Mismatch Repair Deficiency clinical trials at UCSF
2 research studies open to eligible people
Mismatch repair deficiency means that cells struggle to repair DNA errors. UCSF is examining how artificial intelligence can improve choosing the right cancer trials for patients. Another study at UCSF is investigating the effectiveness of RP1 by itself and with another drug, nivolumab.
RP1 Monotherapy and RP1 in Combination With Nivolumab
open to eligible people ages 18 years and up
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
San Francisco, California and other locations
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
open to all eligible people
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
San Francisco, California and other locations
Our lead scientists for Mismatch Repair Deficiency research studies include Katy Tsai, MD.
Last updated: